Inside the DNA of 84 adults living with HIV, something had shifted over eight months. Not the genetic code itself, but the chemical tags sitting on top of it, the molecular sticky notes that tell genes when to switch on and off. Half the group had spent the trial injecting themselves weekly with semaglutide, the same compound sold as Ozempic and Wegovy. And when researchers read those chemical tags at the end, the semaglutide group looked, by several biological measures, a little younger than they should have.
This is the first randomized, placebo-controlled human evidence that a GLP-1 drug might do more than shrink waistlines and steady blood sugar. It might also slow some of the molecular clockwork of aging.
The clocks in question are not the kind on your wall. They are statistical models, built from patterns of DNA methylation, those chemical marks that accumulate and rearrange as we get older. Feed a blood sample into one of these epigenetic clocks and it spits out a biological age, which can run ahead of or behind the number on your birth certificate. People with HIV tend to run ahead. Even when the virus is well controlled by antiretroviral therapy, their bodies often age faster than expected, which makes them, in a slightly grim way, a useful population for studying aging itself.
The data came from a trial that was never designed to ask this question. Its original goal was measuring fat around the abdomen.
Reading the Clocks
Researchers at the University of California San Diego and partner institutions went back to that finished trial, profiled DNA methylation in blood at the start and at week 32, and ran the numbers through a whole battery of clocks. The pattern that emerged was fairly consistent. Across measures tied to inflammation, blood, brain, heart, kidney, liver and metabolic health, the semaglutide group showed slower biological aging than the placebo group. On one widely used clock called DunedinPACE, which estimates how fast you are aging right now rather than how old you are, the pace dropped by about 9 per cent.
“We are not saying that semaglutide reverses aging or makes people younger,” said Michael Corley, an associate professor of medicine at UC San Diego School of Medicine and the Stein Institute for Research on Aging, who led the work. “What we are seeing is a signal that it may slow some of the biological processes associated with aging.”
Why would a diabetes-and-weight drug touch something as fundamental as aging? The leading explanation is unglamorous: inflammation and fat. Chronic immune activation is one of the main drivers of accelerated aging in people with HIV, and GLP-1 drugs tamp it down. They also strip away visceral and ectopic fat, the stuff that wraps around the abdomen and burrows into organs, which in turn quiets the inflammatory and metabolic signals that seem to push biological aging forward. But Corley suspects there is more going on under the bonnet. “Emerging data also suggest that GLP-1 drugs may reprogram certain cells in different organs, which could help explain why we see effects across multiple aging clocks,” he said. If that holds up, the drugs would be doing something rather deeper than simply melting fat.
The numbers in the published paper are striking on their own terms. PhenoAge slowed by nearly five years per year of follow-up; the mortality-linked PCGrimAge clock by around three; several others by smaller but statistically solid margins.
A Signal, Not a Verdict
A note of caution, though, and the authors are the first to raise it. This was a post hoc analysis, meaning the aging question was bolted on after the fact rather than planned from the start. The sample was modest, the cohort specific, the follow-up just 32 weeks.
It is also not the only hint pointing this way. A companion pilot study, published last month in npj Aging, followed people with HIV and fatty liver disease through 24 weeks of semaglutide. Roughly 42 per cent saw their pace of aging slow on DunedinPACE, and those same people lost more liver fat. About a third showed slowing on the mortality-risk clock. And in nearly half, the telomeres, the protective caps on the ends of chromosomes that fray with age, actually got longer; those participants tended to walk faster afterwards, a small but tangible sign of better physical function. Two studies, same direction of travel. That is the sort of thing that gets a field interested.
The obvious question is whether any of this matters for people who do not have HIV. Corley thinks it might. “Many of the biological processes we study in HIV are also central to aging in the general population,” he said, adding that because those processes show up earlier and more sharply in this community, it can help researchers spot interventions that improve healthspan for everyone. Whether the effect would be as pronounced in a healthier, slower-aging body is anyone’s guess for now. Larger trials will need to sort out dosing, how long the benefits last, and whether stacking the drug on top of better sleep, diet and exercise amplifies anything.
There is a whiff of irony here. A class of drugs currently famous for what it does to appearance may turn out to matter more for what it does invisibly, in the methylation patterns no mirror will ever show you. The Stein Institute is already talking about building individualized “aging dashboards” that track these clocks and let clinicians tune therapies to the specific machinery going wrong in a given patient. Whether semaglutide earns a permanent place on that dashboard, or gets eclipsed by the newer GLP-1 compounds now arriving, is exactly the question the next round of trials will have to answer.
Source: Corley et al., Nature Communications (2026), DOI 10.1038/s41467-026-72861-3
Frequently Asked Questions
Does this mean Ozempic can make you age more slowly?
Not exactly, and the researchers are careful about the wording. In this trial semaglutide slowed several biological markers of aging in the blood, but slowing a molecular clock is not the same as proven longer or healthier life. It is an early signal worth chasing, not a verdict, and it has only been shown so far in a specific group of people living with HIV.
How can a drug change your biological age without changing your DNA?
The clocks used here do not read your genetic code; they read chemical marks called methylation that sit on top of it and shift with age, stress and inflammation. Semaglutide appears to nudge those marks toward a younger-looking pattern, probably by lowering inflammation and stripping away fat around the organs. Some researchers suspect it may also reprogram cells in various organs, which would explain why the effect showed up across so many different clocks.
Why study people with HIV to learn about aging?
People with well-controlled HIV often age faster biologically than expected, so the processes behind aging tend to appear earlier and more strongly in them. That makes the group a kind of accelerated test case, where an anti-aging effect is easier to detect over a short trial. Whether the same benefit carries over to healthier bodies is one of the big open questions the next trials aim to settle.
How solid is the evidence at this stage?
It is promising but preliminary. The main finding came from a post hoc analysis, meaning the aging question was added after a trial designed to study abdominal fat, with fewer than 90 participants and only 32 weeks of follow-up. A separate pilot study points the same way, which is encouraging, but larger trials built specifically to test aging are needed before anyone draws firm conclusions.
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.